To build a vaccine production line, the drug company plans to buy 340 million properties

On September 7, Tibet Pharmaceuticals announced that it intends to purchase real estate from Huaping Development for the construction of a production line for the sixth phase of the Lingang Zhiming Park project in Fengxian Park, Lingang, Shanghai, China.
Tibet Pharmaceuticals said that the first phase of the proposed purchase of housing construction area of about 274,000 square meters, the unit price of about 10,500 yuan / per square meter (the final transaction price is based on the third-party assessment price), a total of about 288 million yuan, the relevant housing sales contract has not yet been signed;
the total amount of the above-mentioned houses and land is estimated to be about $340 million.
announced on June 15 this year that it would invest 351 million yuan in the development, registration, production, use and commercialization of the vaccine in phases, in cooperation with S Microbiology.
the latter is mainly mRNA vaccine.
tibet pharmaceutical company said on its interactive platform in mid-August that it had paid an advance of 35 million yuan (including taxes) under a strategic cooperation agreement with sri-society.
, mRNA vaccines express viral protein antigens in cells by importing mRNA encoded viral antigens directly into the body.
the vaccine does not pose a risk of infection or mutation, is more stable and translates more efficiently, while the development of delivery methods enables mRNA to be delivered quickly to cells to function.
addition, the mRNA vaccine is expected to be ready within 40 days of the production of vaccine samples, compared to the 5-6 month production cycle of conventional vaccines, so it is expected to better respond to outbreaks of infectious diseases.
It is worth mentioning that since May 22 this year, Tibet Pharmaceuticals' share price has soared, from 25.92 yuan per share to 182.07 yuan per share on August 4, and has since started to swing down, closing at 83.53 yuan per share as of September 7.
first half of 2020 was relatively flat compared with its frenzied share price.
On the evening of August 10, Tibet Pharmaceuticals released its 2020 Mid-Year Report, during which it achieved operating income of 629 million yuan, up 1.57 percent year-on-year, and net profit attributable to shareholders of listed companies of 220 million yuan, up 39.76 percent year-on-year.
first half of 2020, net cash flow from pharmaceutical operations in Tibet was 187 million yuan, down 49.30 percent year-on-year.
half-yearly report said that sales returns received in the current period decreased by 114 million yuan yoY, as well as the market fees paid increased by 70 million yuan YoY and other common effects.
same time, tibet's pharmaceutical industry's operating costs rose, faster than revenue, up 5.66 percent year-on-year.
company has received several previous exchange inquiries about stock movements, the company also said that there is no disclosure but not disclosed significant matters.
On June 16, Tibet Pharmaceuticals issued an announcement on foreign investment, in cooperation with S micro (Shanghai) Biotechnology Co., Ltd., which has only the right to develop, produce, use and commercialize the vaccine globally and is not the owner of the relevant vaccine.
Public information shows that Tibet Pharmaceutical Industry is employed in the pharmaceutical manufacturing industry, mainly in the production and sale of capsules, biologics, granules, film coating agents, etc. , the main products related to cardiovascular, liver and bile, sprains and rheumatism, rheumatism, cold and other fields.
Tibet pharmaceutical industry tips risk said that the purchase of real estate, is to prepare for the construction of vaccine production lines, if the vaccine research and development failure, has been paid to the microorganism funds, related clinical costs are irrecru recoverable risk, the purchase of real estate will be converted to other uses or sold.